Harris Matthew Scott 4
4 · Altimmune, Inc. · Filed Feb 5, 2024
Insider Transaction Report
Form 4
Harris Matthew Scott
Chief Medical Officer
Transactions
- Exercise/Conversion
Restricted Stock Units
2024-02-01−6,166→ 6,166 total→ Common Stock, par value $0.0001 (6,166 underlying) - Exercise/Conversion
Restricted Stock Units
2024-02-02−7,775→ 15,550 total→ Common Stock, par value $0.0001 (7,775 underlying) - Tax Payment
Common Stock, par value $0.0001
2024-02-02$9.32/sh−2,332$21,734→ 53,633 total - Exercise/Conversion
Common Stock, par value $0.0001
2024-02-01+6,166→ 49,991 total - Exercise/Conversion
Common Stock, par value $0.0001
2024-02-02+7,775→ 55,965 total - Tax Payment
Common Stock, par value $0.0001
2024-02-01$9.88/sh−1,801$17,794→ 48,190 total
Footnotes (4)
- [F1]Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.0001, when vested.
- [F2]Vesting transaction: Shares surrendered to the Issuer solely to cover taxes associated with vesting of RSUs.
- [F3]The RSUs become vested in substantially equal annual installments over the 4 years following February 1, 2021, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.
- [F4]The RSUs become vested in substantially equal annual installments over the 4 years following February 2, 2022, subject to the reporting person's continued service through the applicable vesting date, and have no expiration date.